Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
Authors
Keywords
Colitis, Diarrhea, Immune checkpoint inhibitors, Immunotherapy, Infliximab, Vedolizumab
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-04-02
DOI
10.1186/s40425-019-0577-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma
- (2019) Hamzah Abu-Sbeih et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
- (2019) Filipe Martins et al. LANCET ONCOLOGY
- Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
- (2018) Yinghong Wang et al. INFLAMMATORY BOWEL DISEASES
- Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
- (2018) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
- (2018) John A. Thompson Journal of the National Comprehensive Cancer Network
- Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
- (2018) Yinghong Wang et al. Journal for ImmunoTherapy of Cancer
- Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?
- (2018) Kati Choi et al. INFLAMMATORY BOWEL DISEASES
- Management of inflammatory bowel disease
- (2018) Emily K Wright et al. MEDICAL JOURNAL OF AUSTRALIA
- Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
- (2018) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
- (2018) Yinghong Wang et al. NATURE MEDICINE
- Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
- (2018) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
- (2018) Daniel H Johnson et al. Journal for ImmunoTherapy of Cancer
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study
- (2017) Akbar K Waljee et al. BMJ-British Medical Journal
- Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study
- (2017) Akbar K Waljee et al. BMJ-British Medical Journal
- Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
- (2017) Michael Dougan Frontiers in Immunology
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
- (2016) Eduard Cornelis Verschuren et al. Clinical Gastroenterology and Hepatology
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Harnessing the Microbiome to Enhance Cancer Immunotherapy
- (2015) Michelle H. Nelson et al. Journal of Immunology Research
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis
- (2008) J N Hoes et al. ANNALS OF THE RHEUMATIC DISEASES
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
- (2008) Geert D'Haens et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More